Bank of America’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Bank of America’s Portfolio CMPI Stock Details CMPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	–	–	8778
2022 Q1	$0	Sell	1 -1,111	-100%	-$3.19K	﹤0.01%	9091
2021 Q4	$4K	Sell	1,112 -2,258	-67%	-$8.41K	﹤0.01%	7912
2021 Q3	$14K	Sell	3,370 -2,961	-47%	-$15.2K	﹤0.01%	7500
2021 Q2	$37K	Sell	6,331 -4,033	-39%	-$28.5K	﹤0.01%	6955
2021 Q1	$126K	Buy	10,364 +5,994	+137%	+$85.2K	﹤0.01%	6295
2020 Q4	$64K	Buy	4,370 +1,000	+30%	+$12.7K	﹤0.01%	6224
2020 Q3	$39K	Buy	+3,370	New	+$43.2K	﹤0.01%	6105

Bank of America's CMPI Position: Q2 2022 in Review

Bank of America sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2022, closing a stake of 1 share.

Bank of America first reported a position in CMPI in Q3 2020 and held it in 7 quarters. The position peaked at $126K in Q1 2021. 0 funds tracked by Wall St. Rank hold CMPI as of Q2 2022.

Bank of America reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Bank of America sold 1 Checkmate Pharmaceuticals, Inc. Common Stock share in Q2 2022.
Bank of America first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
Bank of America's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $126K in Q1 2021.
0 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Bank of America's 13F filing for Q2 2022, filed 12 Aug 2022.